Author

N. Zila

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Assay:multiome· 1

Frequent Co-Authors

A. Aloia· 1 shared A. Bileck· 1 shared A. Dzung· 1 shared A. Irmisch· 1 shared A. Leitner· 1 shared A. Nawrocki· 1 shared A. Othman· 1 shared A. Saltari· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Aloia

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function

S. Bromberger, Y. Zadorozhna, J. M. Ressler, S. Holzner, A. Nawrocki, N. Zila, A. Springer, M. R. Larsen, K. Schossleitner

This study investigates off-target effects of BRAF inhibitors on endothelial cells, revealing differential impacts on vascular barrier function and signaling.

bioRxiv · Aug 24, 2023 · PreprintCell Biology

ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma

O. M. Eichhoff, C. I. Stoffel, J. Kaesler, L. Briker, P. Turko, G. Karsai, N. Zila, V. Paulitschke, P. F. Cheng, A. Leitner, A. Bileck, N. Zamboni, A. Irmisch, Z. Balazs, A. Tastanova, , M. Levesque

The paper identifies ROS induction as a strategy to target MEK-inhibitor resistant NRAS-mutated melanoma cells by exploiting their quiescent metabolic state and elevated baseline ROS levels.

bioRxiv · Oct 19, 2022 · PreprintCancer Biology